Panacea Life Sciences Holdings Inc
Panacea Life Sciences Holdings, Inc., operates as a holding company, researchers, develops, manufactures, produces, and distributes cannabinoids, mushrooms, kratom, and other natural, plant-based ingredients and products for humans and animals. It provides a range of products, including Nitro Kava, Kratom, hemp, VAPE products, and various beverages that focuses on promoting alternative health and… Read more
Panacea Life Sciences Holdings Inc (PLSH) - Total Assets
Latest total assets as of September 2025: $3.98 Million USD
Based on the latest financial reports, Panacea Life Sciences Holdings Inc (PLSH) holds total assets worth $3.98 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Panacea Life Sciences Holdings Inc - Total Assets Trend (2017–2023)
This chart illustrates how Panacea Life Sciences Holdings Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Panacea Life Sciences Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Panacea Life Sciences Holdings Inc's total assets of $3.98 Million consist of 25.9% current assets and 74.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.6% |
| Accounts Receivable | $263.97K | 1.5% |
| Inventory | $4.01 Million | 22.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $3.01 Million | 16.8% |
Asset Composition Trend (2017–2023)
This chart illustrates how Panacea Life Sciences Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Panacea Life Sciences Holdings Inc's current assets represent 25.9% of total assets in 2023, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2023, down from 93.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 22.3% of total assets.
Panacea Life Sciences Holdings Inc Competitors by Total Assets
Key competitors of Panacea Life Sciences Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Panacea Life Sciences Holdings Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Panacea Life Sciences Holdings Inc generates 0.13x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Panacea Life Sciences Holdings Inc is currently not profitable relative to its asset base.
Panacea Life Sciences Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.75 | 0.22 | 0.23 |
| Quick Ratio | 0.04 | 0.03 | 0.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.45 Million | $ -17.27 Million | $ -3.65 Million |
Panacea Life Sciences Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Panacea Life Sciences Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.28 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -7.7% |
| Total Assets | $17.98 Million |
| Market Capitalization | $500.75K USD |
Valuation Analysis
Below Book Valuation: The market values Panacea Life Sciences Holdings Inc's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Panacea Life Sciences Holdings Inc's assets decreased by 7.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Panacea Life Sciences Holdings Inc (2017–2023)
The table below shows the annual total assets of Panacea Life Sciences Holdings Inc from 2017 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $17.98 Million | -7.73% |
| 2022-12-31 | $19.49 Million | -18.06% |
| 2021-12-31 | $23.78 Million | +33272.13% |
| 2020-12-31 | $71.27K | -99.27% |
| 2019-12-31 | $9.80 Million | +68474.37% |
| 2018-12-31 | $14.29K | -91.72% |
| 2017-12-31 | $172.67K | -- |